ALEC - Alector, Inc.
IEX Last Trade
1.795
0 0%
Share volume: 6,360
Last Updated: Fri 27 Dec 2024 05:30:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$1.80
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
19%
Liquidity
67%
Performance
16%
Performance
5 Days
-3.65%
1 Month
-28.02%
3 Months
-61.54%
6 Months
-57.18%
1 Year
-76.88%
2 Year
-79.07%
Key data
Stock price
$1.80
DAY RANGE
$1.76 - $1.85
52 WEEK RANGE
$1.86 - $8.90
52 WEEK CHANGE
-$76.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Arnon Rosenthal
Region: US
Website: alector.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alector.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.
Recent news